Phase I/II study of multipeptide cancer vaccine IMA901 after single-dose cyclophosphamide in Japanese patients with advanced renal cell cancer with long-term follow up.
Fumiya HongoTakashi UedaNatsuki TakahaSatoshi TamadaTatsuya NakataniTsuneharu MikiOsamu UkimuraPublished in: International journal of urology : official journal of the Japanese Urological Association (2022)
This study demonstrated the safety and tolerability of IMA901 vaccine in Japanese RCC patients, and also showed that vaccination elicited an immune response.